Under this agreement, Emmaus will commercialize NutreStore, which is approved by the FDA for use in combination with human growth hormone as a treatment for short bowel syndrome (SBS). Emmaus will be introducing NutreStore in the spring of 2008 and projects that its sales will greatly contribute to its short and long term financial performance of the company.
Joel Eisner, associate principal of Cato BioVentures, said: “Cato BioVentures is excited to partner with Emmaus Medical for the marketing of NutreStore and looks forward to a long and successful relationship with the company.”